title: The Challenges Faced in Developing Novel Drug Radiation Combinations in Non-small Cell Lung Cancer.
abstract: Lung cancer is the most common cancer diagnosed in the UK. Outcomes for patients with this disease remain poor and new strategies to treat this disease require investigation. One potential option is to combine novel agents with radiotherapy in clinical studies. Here we discuss some of the important issues to consider when combining novel agents with radiotherapy, together with potential solutions as discussed at a recent Clinical Translational Radiotherapy Group (CTRad) workshop.
authors: Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK. Electronic address: Stephen.Harrow@ggc.scot.nhs.uk.
authors: S
authors: S
authors: Harrow
authors: Centre for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, UK.
authors: G G
authors: GG
authors: Hanna
authors: The University of Manchester, Manchester Academic Health Science Centre, Institute of Cancer Sciences, Manchester Cancer Research Centre, Manchester, UK.
authors: C
authors: C
authors: Faivre-Finn
authors: The Royal Marsden Hospital, London, UK.
authors: F
authors: F
authors: McDonald
authors: Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
authors: A J
authors: AJ
authors: Chalmers
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents
keywords: DNA damage repair; NSCLC; immunotherapy; radiotherapy; umbrella study